Better Dairy Secures US Self-Affirmed GRAS for Fermented Lactopontin
UK biotech Better Dairy has achieved self-affirmed GRAS status in the United States for precision-fermented lactopontin, clearing the regulatory path for commercial supplement formulation.
AI-assisted coverage: produced by SF News' automated newsroom from the cited sources and checked by automated attribution gates. Editorial responsibility: Lee Smith, Group CEO. How we work →
London, United Kingdom — 24 May 2024
Better Dairy has secured self-affirmed GRAS (Generally Recognised as Safe) status for its precision-fermented lactopontin, clearing an immediate regulatory route for commercial supply into the United States functional nutrition and dietary supplement sectors. Lactopontin, also identified as milk osteopontin, is a multifunctional phosphorylated glycoprotein naturally present in mammalian milk that regulates biological signalling pathways tied to tissue growth, muscular renewal, and cellular repair.
Although clinical researchers have long tracked the physiological utility of lactopontin, conventional dairy processing cannot deliver the protein at commercial scale. Natural concentrations within bovine whey are minimal, requiring unsustainable volumes of raw milk to isolate usable quantities. The resulting cost per kilogram has historically priced the ingredient out of commercial sports nutrition, active longevity, and clinical nutrition formulas. By deploying microbial fermentation hosts, Better Dairy produces an identical recombinant protein without reliance on animal extraction.
The move aligns with broader commercial efforts across North America to commercialise high-value bio-identical dairy fractions, including lactoferrin and individual casein profiles. For contract development and manufacturing organisations (CDMOs), precision-fermented bio-actives introduce predictable batch consistency, absence of lactose and standard dairy allergens, and defined input costs insulated from farm-gate milk price fluctuations.
What this means for United States
For US brand owners and co-packers, self-affirmed GRAS enables immediate SKU development across recovery powders, ready-to-drink formulations, and capsule delivery formats. Regulatory teams must ensure batch safety dossiers align with FDA consensus thresholds to withstand prospective retail scrutiny from national chains like CVS and specialty outlets. Commercially, early adopters targeting the premium sports recovery and musculoskeletal repair segments can capture margins above 45% by marketing an exclusive bio-active fraction that competitors sourcing standard dairy isolates cannot supply. R&D heads must run accelerated heat stability and solubility trials before initiating high-speed commercial bottling or powder-fill production.
Many leading brands in this category are manufactured in partnership with Supplement Factory.